Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 1/2021

Open Access 01-01-2021 | Lymphoma | Letter to the Editor

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

Authors: Annalen Bleckmann, Sascha Dierks, Hans-Ulrich Schildhaus, Niels Hellige, Ulrike Bacher, Lorenz Trümper, Gerald Wulf

Published in: Annals of Hematology | Issue 1/2021

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S (2012) Burkitt’s lymphoma. Lancet. 379(9822):1234–1244CrossRef
2.
Dunleavy K, Little RF, Wilson WH (2016) Update on Burkitt lymphoma. Hematol Oncol Clin North Am 30(6):1333–1343CrossRef
3.
Meadows SA, Vega F, Kashishian A et al (2012) PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 119(8):1897–1900CrossRef
4.
Graf SA, Gopal AK (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17(2):265–274CrossRef
5.
Davies A (2015) Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes. Expert Rev Hematol 8(5):581–593CrossRef
6.
Love C, Sun Z, Jima D et al (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44(12):1321–1325CrossRef
7.
Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, Thiel E (2005) Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia. 19(8):1391–1398CrossRef
8.
Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM (2014) Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 4(2)
9.
Wan G, Pehlke C, Pepermans R, Cannon JL, Lidke D, Rajput A (2015) The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells. Cell Death Discov 1:15044CrossRef
10.
Sheen MR, Marotti JD, Allegrezza MJ, Rutkowski M, Conejo-Garcia JR, Fiering S (2016) Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 5(10):e267CrossRef
11.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R (2012) PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 3(12):1566–1575CrossRef
12.
Curnock AP, Knox KA (1998) LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells. Cell Immunol 187(2):77–87CrossRef
13.
Spender LC, Inman GJ (2014) Developments in Burkitt’s lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res 6:27–38PubMedPubMedCentral
14.
Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R (2013) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73(1):276–284CrossRef
Metadata
Title
Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
Authors
Annalen Bleckmann
Sascha Dierks
Hans-Ulrich Schildhaus
Niels Hellige
Ulrike Bacher
Lorenz Trümper
Gerald Wulf
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 1/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-020-03974-y

Other articles of this Issue 1/2021

Annals of Hematology 1/2021 Go to the issue

Letter to the Editor

Congenital dyserythropoietic anemia type IV with high fetal hemoglobin caused by heterozygous KLF1 p.Glu325Lys: first report in an Indian infant

Correction

Correction to: Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma—not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry

Letter to the Editor

A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient

Original Article

Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection

Original Article

Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas

Letter to the Editor

An atypical chronic neutrophilic leukemia patient harboring ASXL1 and NRAS mutations associated with monoclonal plasma cell dyscrasia presenting as hemopericardium
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits